載入...
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals
BACKGROUND: Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offer two options for interferon-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/rib...
Na minha lista:
| Main Authors: | , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4077973/ https://ncbi.nlm.nih.gov/pubmed/24677184 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27151 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|